Hormone receptor-positive breast cancer again takes centre stage at the ASCO 23 (American Society of Clinical Oncology) Annual Meeting and has reinvented itself over the last two decades. Improvements are occurring in the adjuvant and neoadjuvant setting for both estrogen (ER) and progesterone (PR) positive and the human epidermal growth factor receptor space (HER2). In this episode, Michael and Josh take a closer look at MonarchE (Abemaciclib), NATALEE (Ribociclib), PHERgain (dose de-escalation) and Penelope-B (ctDNA).

As the arsenal for treating breast cancer grows, a crowded space means ongoing challenges with sequencing and choice of therapy.

Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.

Studies:

MonarchE: https://meetings.asco.org/abstracts-presentations/218406

NATALEE: https://meetings.asco.org/abstracts-presentations/218407

PHERgain: https://meetings.asco.org/abstracts-presentations/219848

Penelope-B: https://meetings.asco.org/abstracts-presentations/220878

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.